Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab and Cyclophosphamide in Relapsed/Refractory AML and Higher-Risk MDS
NCT03417154Phase 2Completed
- Sponsor
- Masonic Cancer Center
- Start
- Aug 2018
- Primary completion
- Jan 2022
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab, cyclophosphamide in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by Masonic Cancer Center. Started Aug 2018; status: completed.
02
Drugs
nivolumabcyclophosphamide
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT03417154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03417154.